Fig. 6: Antiviral activity of combinations of Mpro and PLpro inhibitors.
From: Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
Effect of combination of Mpro inhibitor MG-101 and PLpro inhibitor Sitagliptin on the growth of SARS-CoV-2 (a) and the delta variant (b) (n = 3). Huh7.5 cells were treated with the inhibitors as shown, and reduction in virus titer at 24 h.p.i. was determined by plaque assays. Data are shown as mean ± SEM. p Values were considered significant when p < 0.05 (*), p < 0.01 (**), p < 0.001(***), and p < 0.0001(****).
